MediWound (NASDAQ:MDWD - Get Free Report) will likely be releasing its earnings data before the market opens on Wednesday, March 19th. Analysts expect MediWound to post earnings of ($0.61) per share and revenue of $5.79 million for the quarter. Persons interested in participating in the company's earnings conference call can do so using this link.
MediWound Trading Up 3.7 %
Shares of NASDAQ:MDWD opened at $17.21 on Wednesday. The firm has a market cap of $185.63 million, a price-to-earnings ratio of -5.93 and a beta of 0.82. The stock's 50-day moving average price is $18.02 and its two-hundred day moving average price is $17.60. MediWound has a 12-month low of $12.78 and a 12-month high of $24.00.
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on MDWD shares. HC Wainwright restated a "buy" rating and issued a $25.00 target price on shares of MediWound in a report on Friday, January 10th. Craig Hallum initiated coverage on shares of MediWound in a report on Friday, February 28th. They issued a "buy" rating and a $39.00 price target on the stock.
Check Out Our Latest Analysis on MDWD
About MediWound
(
Get Free Report)
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
